Grifols (GRFS) Projected to Announce Quarterly Earnings on Tuesday

Grifols (NASDAQ:GRFS) will likely be releasing its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect Grifols to announce earnings of $0.28 per share and revenue of $2.1794 billion for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, July 28, 2026 at 12:30 PM ET.

Grifols Price Performance

Shares of NASDAQ:GRFS opened at $7.58 on Friday. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.47 and a quick ratio of 0.85. Grifols has a 1-year low of $6.96 and a 1-year high of $11.14. The company has a market capitalization of $5.16 billion, a P/E ratio of 39.89, a P/E/G ratio of 0.29 and a beta of 0.67. The firm’s 50 day simple moving average is $7.51 and its two-hundred day simple moving average is $8.22.

Grifols Dividend Announcement

The company also recently disclosed a special dividend, which was paid on Thursday, July 9th. Stockholders of record on Thursday, July 2nd were paid a $0.0945 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. Grifols’s dividend payout ratio is 121.05%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Corient Private Wealth LLC increased its stake in Grifols by 30.7% in the 4th quarter. Corient Private Wealth LLC now owns 63,767 shares of the biotechnology company’s stock worth $592,000 after acquiring an additional 14,968 shares during the last quarter. OLD Mission Capital LLC bought a new position in Grifols during the fourth quarter valued at $1,063,000. Millennium Management LLC grew its stake in shares of Grifols by 2.7% in the 4th quarter. Millennium Management LLC now owns 7,122,155 shares of the biotechnology company’s stock worth $66,592,000 after buying an additional 184,874 shares in the last quarter. Abel Hall LLC purchased a new position in shares of Grifols in the 4th quarter worth $330,000. Finally, Vinva Investment Management Ltd increased its holdings in shares of Grifols by 10.0% in the 4th quarter. Vinva Investment Management Ltd now owns 28,223 shares of the biotechnology company’s stock worth $264,000 after buying an additional 2,558 shares during the last quarter.

Analysts Set New Price Targets

A number of research firms recently weighed in on GRFS. Wall Street Zen cut shares of Grifols from a “buy” rating to a “hold” rating in a research note on Monday, May 18th. Weiss Ratings lowered Grifols from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. Finally, Zacks Research raised Grifols from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Three investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus target price of $10.00.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.